NFKB1 and cancer: Importantly, BMX-001 likely promotes mild redox modulation that stabilizes Nrf2 and suppresses NF-κB in normal cells, like SGCs, without benefiting cancer cells, where the Nrf2 pathway may already be dysregulated [25].